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Characterization of anti-GBM antibodies involved in Goodpasture's
syndrome. Goodpasture's syndrome is a life threatening autoimmune
kidney disease. The patients have autoantibodies to the glomerular
basement membrane, which are specific for the C-terminal domain of type
IV collagen (Nd). The major antigen has been localized to the a3(IV)-
chain. We have investigated sera from 44 patients with anti-NC1 antibod-
ies. The quantity of antibodies to four different a(IV)-chains of type IV
collagen was measured with direct ELISA. We used affinity chromatog-
raphy to separate the antibodies and their specificities were studied with
ELISA. The results show that about 1% of the patients total IgG are
anti-NC1 antibodies and that 90% of these antibodies are specific for the
a3(IV)-chain. Antibodies to the other a(IV)-chains were found in 80% of
the patients. Furthermore, affinity purified anti-a3(IV) antibodies from
one patient were inhibited by antibodies from the other patients, from 4 to
72%. The antibodies, from 39 of the patients, were inhibited by a
monoclonal antibody against the a3(IV)-chain. The results indicate that
patients with Goodpasture's syndrome can have antibodies to most of the
a(IV)-chains, while the majority of anti-NC1 antibodies are restricted to
the a3(IV)-chain. Moreover the number of epitopes seems to be limited
and the majority of the antibodies from most patients are against one
single epitope on the a3(IV)-chain.
Goodpasture's syndrome (GP) is a very severe autoimmune
disorder, and it is the classic example of an antibody-mediated
glomerulonephritis. It typically affects individuals in the third and
in the sixth decades, but may appear at any age [1]. The disease is
characterized by rapidly progressive glomerulonephritis, lung
hemorrhage and a linear deposit of IgG along the glomerular
basement membrane (GBM) [2]. The pulmonary hemorrhage
may be severe and life threatening or may be mild and easily
overlooked [3, 4]. Still, the rapidly progressive glomerulonephritis
is the most common clinical feature of the syndrome.
It is now firmly established that the anti-GBM antibodies in GP
are directed to type IV collagen, which is one of the main
structural components in basement membranes. The type IV
collagen molecule is composed of three a(IV)-chains. In the
N-terminal and middle region the three a(IV)-chains are inter-
twined to a triple helix structure, while in the C-terminal region
each chain is folded into a globular domain. This globular domain
is called NC1 (non-collagenous). Normally, type IV collagen is
composed of two distinct a(IV)-chains, the classical al(IV) and
a2(IV) [5]. However, in GBM three additional a(IV)-chains have
been identified, a3(IV), a4(IV) and a5(IV) [6, 7]. The gene for a
sixth, a6(IV) has recently been discovered [8]. It has been shown
that a3(IV) and a4(IV)-chains co-localize and are only present in
specialized basement membranes, for example in the kidney, eye,
cochlea, lung and brain, whereas the al(IV)- and a2(IV)-chains
are present in all basement membranes [9]. Primary results show
that the cs5(IV)-chain also has a limited distribution in different
basement membranes. It has also been shown that in bovine
GBM, the network consisting of 3(IV) and a4(IV) does interact
with the al(IV) and a2(IV) network via the NC! domain creating
hetrodimers, that is, al(IV)-a3(IV) and a2(IV)-a4(IV) [10].
All patients with GP have autoantibodies to the NC1 of the
a3(IV)-chain [1] and these antibodies are believed to be patho-
genetic. Nevertheless, antibodies to the other a(IV)-chains have
been reported, but the significance of these antibodies is un-
known. Antibodies that are eluted from kidneys from GP patients
are shown to have the same specificity as antibodies found in
serum, that is, the majority are to the a3(IV) but there are some
reactivity to the other a(IV)-chains [11]. We have found a few
patients with very mild glomerulonephritis even though they have
anti-GBM antibodies. These patients had antibodies to the NC1
domain of the al(IV)-chain and not to the a3(IV)-chain [12].
Moreover, antibodies from patients with GP show very reduced
reactivity if the NC1 is in its hexameric shape, or if it is reduced
and the disulphide bonds are broken [13].
It is necessary to know and to characterize all epitopes involved
in Goodpasture's syndrome to develop new and better therapeutic
and diagnostic methods and to understand the process of disease.
Several investigators have earlier shown that patients with GP
have antibodies to the cs3(IV)-chain of type IV collagen and it has
been assumed that the a3(IV)-chain is the major antigen. In this
study we have quantified the titer of antibodies in sera from 44
patients with anti-NC1 antibodies and determined the frequency
of antibodies to the different a(IV)-chains. We have, furthermore,
studied whether all GP patients have antibodies to the same
epitope/epitopes on the a3(IV)-chain.
Methods
Patients
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Forty sera and four plasma samples from 44 patients with
anti-NC1 antibodies, detectable in an ELISA, were used. As
negative controls we used sera from healthy blood donors. Serum
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from a patient with anti-GBM antibodies specific for the al(IV)-
chain was used for comparison. This patient is earlier described by
Johansson et a! [12].
Antibodies
Two monoclonal antibodies were used in this study, one to the
al(IV)-chain (Mab 6) and one to the a3(IV)-chain (Mab 17) of
type IV collagen. Both antibodies are described before and well
characterized [14]. Additionally, a monoclonal antibody to the
a5(IV)-chain (Mab A7) [15] and polyclonal antibodies to the
a2(IV) and the a4(IV)-chains, both produced in rabbits [16], were
used.
Preparation of antigens
Glomerular basement membrane was prepared from bovine
kidneys as previously described [17] with some modifications.
Homogenized kidney cortex was extracted overnight at room
temperature with 6 M guanidine-HC1 buffer (50 mi Tris-HCI, pH
7.4, 6 M guanidine-HCI) with 10 mi EDTA and protease inhibi-
tors (5 mtvi benzamidine, 25 mt s-aminocaproic acid, 4 mM
N-ethylmaleimide, 1 mivt phenylmethanesulfonyl fluoride). It was
then centrifuged and the pellet was resuspended in HEPES buffer
(50 mM HEPES, pH 7.5 with 10 mM CaCI2 and protease inhibi-
tors). Digestion with bacterial collagenase (Worthington Bio-
chemical Corporation, Freehold, New Jersey, USA) was per-
formed in HEPES buffer at 37°C for 20 hours with continuous
stirring. The solubilized basement membrane was ultracentri-
fuged and the supernatant was dialyzed against 50 mM Tris-HC1,
pH 7.5, 2 M urea and then applied to a DEAE-Sephacel ion
exchange chromatography column (Pharmacia, Uppsala, Sweden)
equilibrated in the same buffer. The NC1 domain, which does not
bind to the column, was collected and concentrated in an ultra-
filtration cell (YM1O Amicon, Danvers, Massachusetts, USA) and
then dialyzed against 6 M guanidine-HC1 buffer.
The concentrated sample, containing Nd, was boiled for five
minutes, and then applied to a S-200 gel filtration column
(Pharmacia) equilibrated in the 6 M guanidine-HC1 buffer. Frac-
tions from the major peaks, 7S, dimeric a(IV)-chains and mono-
meric a(IV)-chains were pooled and the monomeric pooi was
further separated with reversed-phase HPLC as previously de-
scribed [18]. This gave four monomer populations containing
al(IV), a2(IV), a3(IV) and a4(IV), respectively. The content of
the monomer poois was analyzed by immunoblotting (see below)
using antibodies to the al-5(IV)-chains. Reactivity with the
anti-a5(IV) antibody was found in the al(IV) and in the a2(IV)
pool. No antibodies to the a6(IV)-chain were available.
A fraction of the material that went through the DEAE ion
exchange column was also separated on a S-200 gel filtration
column under non-denaturing conditions (50 mrvi Tris-HCI, pH
7.3, 0.15 M NaCl, 0.02% wt/vol NaN3). The major peak, containing
Nd, was further separated on an affinity column [10] containing
Mab 17, the monoclonal antibody to the a3(IV)NC1 domain. The
material that went through the column contained only al(IV)-
and a2(IV)-chains and this fraction was then used for preparing
an affinity column (see below).
Affinity chromatography
Three affinity chromatography columns were prepared from 2
ml activated agarose gel, Mini Leak, (Kem-En-Tec IS, Copenha-
gen, Denmark). Bovine NC1 containing all a(IV)-chains, a frac-
tion of bovine NC1 containing only al(IV)- and a2(IV)-chains
and the monoclonal anti-a3(IV) antibody (Mab 17) were coupled
by the procedure described in the product insert. The columns
were used as previously described [10]. Briefly, the columns were
equilibrated with starting buffer, 50 mri Tris-HC1, pH 7.5, 0.15 M
NaCl, 0.02% (wt/vol) NaN3. The samples were applied in starting
buffer and eluted with 50 m sodium citrate, pH 4.0, 6 M urea,
0.02% (wt/vol) NaN3. The pH of eluted antibodies was immedi-
ately adjusted to 7.0 and then dialyzed against starting buffer.
Twenty-five milliliters of sera from two patients and 1 ml sera
from five patients were applied to the column containing all
a(IV)-chains. The antibodies that bound the column were eluted
in 3 ml elution buffer; 1 ml was used for isolation of IgG using a
protein G affinity column (Pharmacia). The protein concentra-
tions were estimated by absorbance at 280 nm. Two milliliters
were applied to the column containing al(IV)- and a2(IV)-
chains. The unbound fraction was collected in 9 ml and the bound
antibodies were eluted in 3 ml. One milliliter of each fraction was
used for isolation of IgG.
Elect ropho resis
Sodium dodecylsulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) was done in 10 to 16% gradient gels as described by
Laemmli [19]. The gels were stained with silver according to the
method of Morrissey [20]. Immunoblot experiments were per-
formed on samples that were separated with SDS-PAGE and
transferred to Immobilon'TM PVDF membrane (Millipore, Saint-
Quentin, France) as described by Burnett [21] using a semi-dry
electroblotter as previously described [10].
Enzyme-linked immunosorbent assay (ELISA)
Polystyrene microtiter plates (NUNC Immunoplate, Roskilde,
Denmark) were coated with 100 .d of the separated a(IV)-chains
from bovine GBM, diluted to 0.2 g/ml in 50 mrvi Tris-HCI, pH
7.4, 6 M guanidine-HC1. The plates were incubated overnight at
room temperature and then washed three times with 0.15 M NaC!,
0.05% (vol/vol) Tween 20. One hundred microliters of primary
antibodies diluted in phosphate buffered saline containing 0.2%
(wt!vo!) bovine serum albumin, pH 7.3 (BSA-PBS) (1.5 mM
KH2PO4, 8 mM Na2HPO4, 0.12 M NaC1, 2.5 m'vi KC!, 0.05%
(wt/vol) NaN3) were added to each well. The plates were incu-
bated at room temperature for one hour and after washing,
alkaline phosphatase-conjugated swine anti-human IgG, diluted
1/500, (Orion Diagnostica AB, Trosa, Sweden) was added and
incubated for one hour. P-nitrophenyl phosphate (1 mg/mI; Sigma
Chemical Company, St. Louis, Missouri, USA) in substrate buffer
(1 M Dietanolamin, 0.5 mivi MgCl2, pH 9.8), was used as substrate
and color development was measured spectrophotometrically at
405 nm.
For inhibition ELISA affinity-purified antibodies or sera were
diluted and preincubated overnight at 4°C in a preindubation
plate with different a(IV)-chains, in concentrations from 0.005 to
20 ig/ml. The solutions were then added to microtiter plates
coated with al(IV) or a3(IV) (0.2 g/ml). Bound antibodies were
detected with alkaline phosphatase-conjugated secondary anti-
bodies.
In the competitive ELISA, biotinylated affinity purified anti-
a3(IV) antibodies from one patient were used. The antibodies
were biotinylated, using NHS-LC-Biotin, according to the instruc-
tions provided by the manufacturer (Pierce, Rockford, Illinois,
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Table 1. Showing number of dilutions needed to reach 0.5 absorbance
units after 1 hour of development time in ELISA with the four different
a(IV) chains as antigens
Number of dilutions to reach
0.5 Abs units Inhibition %
USA). Biotinylated antibodies, diluted 1/200, were premixed with
patient serum or plasma in different dilutions and then added to
coated microtiter plates and further treated as above. In this assay
bovine a3(IV) was used for coating (0.2 g/ml) and alkaline
phosphatase-conjugated avidin (Pierce) was used as conjugate.
By using the monoclonal antibody to a3(IV), Mab 17, another
competitive ELISA was developed. The culture supernatant with
the monoclonal antibody, diluted 1/20, were premixed with pa-
tient serum or plasma diluted to be equally concentrated, to give
an absorbance value of 0.5 in sandwich ELISA. The mixture was
added to a microtiter plate, coated with bovine a3(IV) (0.2
g/ml). Human antibodies, that bound to the coat, were detected
with phosphatase-conjugated secondary antibodies.
Results
Antibody specificity measured by direct ELISA
Forty sera and four plasma samples from patients with anti-
NC1 antibodies were tested in a sandwich ELISA. Sera from
healthy blood donors and serum from a patient with antibodies
against al(IV), but not to a3(IV)-chains, were used as controls.
The plates were coated with bovine al(IV), a2(IV), cv3(IV) or
a4(IV). To be able to compare the titer of antibodies directed to
the different a(IV)-chains the sera were diluted to give 0.5
absorbance units after one hour development time. The number
of dilutions that are needed is shown in Table 1. This shows that
the majority of the antibodies are directed to cr3(IV) and that
most patients (80%) have a response to the other a(IV)-chains,
even though it is weaker than the response to the a3(IV)-chain.
Many patients with elevated levels of anti-al(IV) also have
anti-a4(IV) antibodies, while findings of anti-a2(IV) antibodies
seem to be more rare. In some patients there are very small
differences between the antibody titers to the different a(IV)-
chains. This is, in most cases, due to a low anti-a3(IV) titer rather
than a high titer of antibodies to other a(IV)-chains. On average,
the samples have to be diluted 14 times more when we are
analyzing anti-a3(IV) antibodies, compared to anti-a 1(IV) anti-
bodies. This indicates that the majority or more than 90% of the
GP antibodies are directed towards the a3(IV)-chain.
Affinity purification of sera
We wanted to find out if the anti-NC1 antibodies were cross
reacting or if there were different antibodies to the different
a(IV)-chains. To do this, we used two affinity columns to isolate
and separate specific anti-NC1 antibodies from seven patients
(sample numbers 11, 12, 14, 18, 19, 20 and 26 in Table 1; Fig. 1).
IgG, from all fractions, was purified with the protein G column,
and the quantity of IgG was measured spectrophotometrically at
280 nm. All antibodies against the NC1 domain of the a(IV)-
chains bound the affinity column containing all a(IV)-chains
(fraction 2, Fig. 1) and no anti-NC1 antibodies were found in the
unbound fraction (fraction 1, Fig. 1). The fraction that bound the
first column (fraction 2, Fig. 1), about 1% (that is in average 0.14
mg/mI) of the patients total IgG, was further separated on an
affinity column containing only al(IV)- and a2(IV)-chains. This
was used to separate antibodies against al(IV) and a2(IV) from
the antibodies against a3(IV) and a4(IV). Only a minor amount
of the anti-NC1 antibodies, 10%, bound to this affinity column
(fraction 4, Fig. 1). This fraction did, however, not only react with
al(IV) and a2(IV) but also with a3(IV) and a4(IV) in a sandwich
Sample
number
al(IV)
as
antigen
a2(IV)
as
antigen
a3(IV)
as
antigen
a4(IV)
as
antigen
Of biotin-labeled
GP antibodies
with patient sera
Of patient
sera with
Mab 17
1 90 40 7200 160 43 100
2 720 60 7100 220 51 63
3 60 — 6300 205 25 66
4 390 50 6200 220 26 61
5 80 30 5500 230 60 45
6 530 70 4300 205 28 44
7 20 — 4000 10 47 68
8 — — 3500 10 42 72
9 600 250 2921 950 27 50
10 — — 2818 90 47 100
11 80 80 2022 120 40 21
12 400 — 2000 120 48 81
13 205 30 1909 170 50 53
14 90 60 1848 105 30 30
15 180 10 1750 70 40 45
16 25 — 1636 50 47 100
17 800 50 1636 390 30 87
18 70 — 1235 — 38 41
19 20 10 935 90 66 68
20 25 — 927 50 34 33
21 20 — 870 — 43 87
22 95 — 836 10 52 98
23 20 — 836 — 62 100
24 — — 818 — 47 90
25 — — 764 — 61 46
26 30 10 685 50 72 47
27 20 — 674 — 24 56
28 — 10 664 — 41 93
29 — — 618 — 44 100
30 30 10 545 120 31 100
31 — 10 345 — 31 100
32 70 270 337 205 9 0
33 — 10 333 — 35 51
34 — 10 315 10 15 37
35 105 — 264 80 52 0
36 20 — 190 — 33 54
37 — — 182 — 49 72
38 — — 164 — 48 98
39 105 — 142 10 25 0
40 75 130 95 50 18 0
41 — — 82 — 56 47
42 70 90 82 50 20 40
43 — — 20 — 47 7
44 — — 15 — 4 0
NS — — — — 0 0
A 870 80 — — 0 0
Samples that do not react with the antigen are indicated with "—". The
inhibition in per cent of the affinity purified a3(IV) specified biotin labeled
antibodies with sera diluted to give the same response in ELISA with the
a3(IV) chain as antigen and the inhibition in per cent of sera diluted to
give the same response in ELISA with the monoclonal antibody to a3(IV)
(Mab 17). The 44 GP sera are indicated with numbers from 1 to 44, one
patient with al(IV) antibodies is indicated with an A and sera from
healthy blood donors are indicated with NS.
ELISA. These antibodies gave a strong response to a3(IV) and
only a weak one against al(IV) in immunoblotting. Using inhibi-
tion ELISA we found two different types of antibodies in this
fraction. For antibodies to al(IV) cross reacting with a2(IV)- and
cs4(IV)-chains and antibodies specific for cs3(IV) but with a low
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Bound fractionSera from patients with GP
• About 1% of total IgG
4,
1. Unbound fraction
• Contains no anti-NC 1
antibodies
1 [Unbound fraction 4. Bound fraction
J
• a3(IV) specific antibodies • Crossreacting antibodies
90% of fraction 2 • Low affinity a3(IV) specific
Fig. 1. The affinity chromatography system used
to punfy and separate antibodies to the NC1
domain of type IV collagen. Column I contains
all four a(IV)-chains whereas column II only
contains al(IV) and a2(IV)-chains. Of all the
anti-NC1 antibodies, 90% were found in
fraction 3 and found to be specific for the
a3(IV)-chain with a high affinity. In fraction 4
(10% of all anti-NC1 antibodies) we found
antibodies to al(IV), cross reacting with a2(IV)
and a4(IV), and anti-a3(IV) antibodies that
differ from the antibodies in fraction 3 by a
lower affinity.
affinity, 5 j.tg/ml c3(IV) were needed for 50% inhibition (Fig. 2 A,
B). Ninety percent of the anti-NC1 antibodies went through the
column containing ui(IV) and u2(IV) (fraction 3, Fig. 1). These
antibodies did only bind to a3(IV) in both ELISA and immuno-
blotting. Furthermore, only 0.5 g/ml a3(IV) were needed for
50% inhibition in an inhibition ELISA. Thus, they were specific
for the a3(IV) and did not cross react with any of the other
a(IV)-ehains (Figure 2 C). These results, that 90% of the anti-
bodies are anti-o3(IV) specific, confirm the results obtained by
the direct ELISA.
We have calculated the quantity of anti-a3(IV) antibodies in
sera from the results by direct ELISA. By measuring the absor-
bance at 280 nm on the affinity purified antibodies from two
patients, we found that an affinity-purified anti-a3(IV)-specific
antibody concentration of 48 rg/ml corresponds to a dilution of
1000 times to reach 0.5 absorbance units after one hour in a direct
ELISA. This gives us, assuming an equal affinity, a mean value of
78 g/ml anti-a3(IV) antibodies (N = 44) which corresponds to a
mean value of 0.8% of the total amount of IgG.
Inhibition of affinity-purified biotin-labeled antibodies
We wanted to find out whether all patients with GP have
anti-cs3(IV) antibodies to the same epitope/s or if different
patients react with different parts of the a3(IV)NC1 domain. The
affinity-purified anti-a3(IV) specific antibodies (fraction 3 in Fig.
1) from one of the patients (number 12 in Table 1) were labeled
with biotin. Serum or plasma from other OP patients, diluted to
give the same response in a direct ELISA, were premixed with the
biotinylated anti-a3(IV) antibodies and then added to a microti-
terplate coated with a3(IV). Forty-four of 44 GP samples could
block the biotinylated anti-a3(IV) from 5 to 70% (Table 1) and
the mean value was 40%. Serum from the same patient that was
biotin labeled did inhibit the reaction to 48%. The relatively low
inhibition is explained by how we performed the experiment, that
is, the samples were very diluted. This is due to our desire to have
all sera equally concentrated, since this result is giving us better
possibilities to detect differences between different samples. If all
sera were diluted 1/25 instead, we obtained an average inhibition
value of 79%, in a range from 49 to 90% (not shown).
Inhibition with a monoclonal anti-cx3(IV) antibody
Earlier investigators have shown that their monoclonal anti-
body to cs3(IV) was able to block the binding of GP patient
antibodies to cx3(IV) [22]. We wanted to investigate if our
monoelonal antibody to a3(IV) (Mab 17) also binds to the same
epitope as antibodies from GP patients and if all anti-a3(IV)
antibodies are to one single epitope that is the same in all patients.
The antibody has been characterized previously and primary
results (not shown) showed that it is possible to inhibit OP sera
from binding to cx3(IV). To further investigate this, a competitive
ELISA was performed. In this, sera from GP patients were
premixed with the monoclonal antibody to a3(IV) and then
transferred to a microtiter plate coated with a3(IV). The antibod-
ies from 39 out of 44 patients were inhibited by the monoclonal
antibody. Twenty-four of these were inhibited from 50 to 100%,
and 13 from 5 to 50%. Besides, there were 5 sera that the
monoclonal did not inhibit at all (Fig. 3). None of the samples was
inhibited by the monoclonal antibody to the al(IV)-chain (Mab
6).
Discussion
About 1% of the total IgG in patients with GP are directed to
the NC1 domain of type IV collagen. Most of these antibodies,
about 90%, are specific for the GP antigen, that is, the NC1
domain of the cr3(IV)-chain. Our theory is that this major
population of antibodies to the a3(IV)-chain are the pathogenetic
antibodies. We found that all patients have antibodies to the
a3(IV)-chain and that 20% of them have antibodies to the
a3(IV)-ehain only, which strongly supports our theory. Almost all
patients (80%) have antibodies not only to the u3(IV)-chain but
also to the other a(TV)-chains and these antibodies represent
about 10% of the anti-NC1 antibodies. In the inhibition ELISA
Column I
Containing ctl (IV), ct2(IV),
a3(IV) and cz4(IV) chains
Column II
Containing ctl(IV)
and cr2(IV) chains
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Fig. 2. Inhibition ELISA where the different fractions from the punfi cation
and separation are inhibited with the different a(JV)-chains. Symbols are:
(g-) inhibition with cd(IV); (4-) inhibition with a2(IV); () inhibition
with a3(IV); (-A-) inhibition with a4(IV). All 7 purified and separated sera
followed the same pattern and one is shown here. A. Fraction 4 in Fig. 1,
the fraction that bound both columns, was tested in a microtiter plate
coated with al(IV). The antibodies were inhibited by al(IV), a2(IV) and
a4(IV)-chains but not by the a3(IV)-chain. B. Fraction 4 was tested in a
microtiter plate coated with a3(IV) and only the a3(IV)-chain was able to
inhibit the antibodies from binding to the a3(IV)-chain. C. Fraction 3 in
Fig. 1, the fraction that bound the column containing all a(IV)-chains but
not the column containing al(IV)- and a2(IV)-chains, was tested in
microtiter plates coated with the a3(IV)-chain. These antibodies were
only inhibited by the a3(IV)-chain. This fraction did not react with any
other a(IV)-chain in direct ELISA.
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these antibodies were cross reactive, which might reflect a sec-
ondary response in which antibodies are produced to other GBM
antigens as the disease progresses. Matsukura et al [231 suggested
that there are GP antibodies with common epitopes present on
al(IV), a2(IV) and a3(IV). These antibodies could be the same
antibodies that we found in the fraction that bound the affinity
column containing csl(IV)- and a2(IV)-chains.
The a5(IV) and a6(IV)-chains have not been isolated, but the
amounts in GBM seem to be limited. The impurities of a5(IV) in
the al(IV) and a2(IV) monomer pools should not have any
influence on the results, since the a3(IV) pool did not contain
a5(IV). However, it is likely that there are antibodies to both
the a5(IV) and the a6(IV)-chains, as well as we find antibodies to the
al(IV), a2(IV) and a4(IV)-chains.
Neilson et al [241 have shown that the specificity of GP
antibodies is to the cc3(IV)-chain, by using recombinant a(IV)-
chains and Kalluri et al [251 have, by using synthetic peptides,
localized the GP epitope to a region of 36 amino acids in the
C-terminal region of the a3(IV)-chain. Pusey et al [22] showed
that a monoclonal antibody, P1, raised against the NC1 domain of
type IV collagen, could block the binding of GP antibodies. In
these earlier studies only a few patients have been included.
However, we have investigated 44 patients with anti-NC1 antibod-
ies and the results support these earlier studies that have sug-
gested a restricted specificity of the GP-antibodies. Our results
show that all patients have antibodies to the same epitopes on the
a3(IV)-chain. This was shown by inhibition of biotin labeled GP
antibodies. Our monoclonal antibody to the a3(IV)-chain could
also inhibit the GP antibodies in 89% of the patients. Thus, the
major fraction of the anti-a3(IV) antibodies, in the majority of the
patients, is to one single epitope. The facts that 16% of the
samples were inhibited to 100% by our monoclonal antibody to
the a3(IV) chain and that one of these only had antibodies to the
a3(IV)-chain suggest that the monoclonal antibody share one
pathogenetic epitope with the GP antibodies. The monoclonal
antibody did not inhibit anti-cc3(IV) antibodies in five samples and
less then 50% in 13. This could be due to different affinities.
Another explanation could be that different patients have differ-
ent, very closely spaced epitopes that both the monoclonal
antibody and the patient's antibody could recognize simulta-
neously. Even though these antibodies do not share exactly the
same epitope as the majority of the anti-a3(IV) antibodies, the
antibodies could still be pathogenetic. Interestingly, the clinical
presentations for two of the patients, whose sera were not
inhibited by the monoclonal antibodies, were entirely different
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from the typical OP patients. Both patients had a milder disease.
The clinical presentation for all patients will be investigated and
this might show whether analysis of the fine specificity of antibod-
ies will be a tool to predict the disease prognosis.
The OP epitope has a cryptic conformation and it is dependent
on correct disulphide bonds. It is normally hidden and the
reaction with OP sera is weak until the epitope is exposed [13].
We have found cross reacting antibodies to the a(IV)-chains as
well as antibodies to areas of the a3(IV)-chain other than the OP
epitope, and these could explain why short synthetic peptides,
which do not contain the GP epitope, still can bind antibodies in
sera of OP patients. In future studies of the OP epitope with
synthetic peptides and recombinant proteins it is important to use
affinity-purified anti-a3(IV) antibodies from patients, whose an-
tibody specificity is well characterized, otherwise it is very likely to
find non-pathogenetic or minor epitopes. It is necessary to
characterize all epitopes involved in OP and to determine which
are pathogenetic, if new and better therapeutic and diagnostic
methods will be developed, and to understand the process of the
disease.
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